Insides buying SQI Diagnostics deal with 5-year warrants (SQD)

Insides buying SQI Diagnostics deal with 5-year warrants (V:SQD)

Clive Beddoe, a Director, acquired 8,333,337 Common Shares on an indirect ownership basis for registered holder Hanover Investments Corporation Ltd. at a price of $0.080 through a prospectus or prospectus exempt offering on March 1st, 2019. The insider also acquired 8,333,337 Warrants with an exercise price of $0.110 for 5 long years. This represents a $666,667 investment into the company's shares and an account share holdings change of 25.1%.

Gerald R. Connor, a Director, acquired 8,258,147 Common Shares on a direct ownership basis and 75,187 Common Shares on an indirect ownership basis for registered holder Registered Accounts. The insider also acquired 8,258,147 Warrants on a direct ownership basis and 75,187 Warrants on an indirect ownership basis for registered holder Registered Accounts. This represents a $666,667 investment into the company's shares and an account share holdings change of 29.5%.

Wilmot Leslie Matthews, a Director, acquired 8,333,334 Common Shares on a direct ownership basis and 8,333,334 Warrants on a direct ownership basis. This represents a $666,667 investment into the company's shares and an account share holdings change of 29.4%.

SQI Diagnostics is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

SQI Diagnostics Inc (SQI) is a Canada-based diagnostics company. The Company develops multiplexed tests and automated systems for customers needing to measure a range of biomarkers in blood or other common sample types. It offers three different platforms sqidlite, sqid x and the siqdworks to run and analyze its microarray plates. Its Ig_plex microarrays have the ability to discriminate between individual isotypes of antibodies and antigens and proteins within a single well of a microarray. Its Ig_plex CHEX technology provides multiple in-microarray checks. It has three areas of focus: Testing for the drug development industry, Animal health testing, Human disease testing or deoxyribonucleic acid (DNA) diagnostic testing. In drug development testing, SQI provides technology and equipment for blood testing in clinical trials and pre-clinical research for developing various drugs. It applies its multiplexing technology to diagnostic tests used for customers in the animal health segment.